Carol Moreno

13.7k total citations · 5 hit papers
155 papers, 5.5k citations indexed

About

Carol Moreno is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Carol Moreno has authored 155 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Genetics, 62 papers in Pathology and Forensic Medicine and 40 papers in Immunology. Recurrent topics in Carol Moreno's work include Chronic Lymphocytic Leukemia Research (91 papers), Lymphoma Diagnosis and Treatment (59 papers) and Immunodeficiency and Autoimmune Disorders (36 papers). Carol Moreno is often cited by papers focused on Chronic Lymphocytic Leukemia Research (91 papers), Lymphoma Diagnosis and Treatment (59 papers) and Immunodeficiency and Autoimmune Disorders (36 papers). Carol Moreno collaborates with scholars based in Spain, United States and Italy. Carol Moreno's co-authors include Emili Montserrat, Richard J. Roman, Jozef Lazar, Paolo Ghia, Howard J. Jacob, Mahesh Mistry, Peter Hillmen, Alessandra Tedeschi, James P. Dean and Thomas J. Kipps and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Carol Moreno

153 papers receiving 5.4k citations

Hit Papers

Ibrutinib plus obinutuzumab versus chlorambucil plus obin... 2018 2026 2020 2023 2018 2019 2019 2022 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
    2018 380 citations Carol Moreno, Alessandra Tedeschi et al. profile →
  2. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
    2019 312 citations Jan A. Burger, Paul M. Barr et al. profile →
  3. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
    2019 307 citations Susan O’Brien, Paul M. Barr et al. profile →
  4. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 
    2022 146 citations Paul M. Barr, Carolyn Owen et al. Blood Advances profile →
  5. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
    2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carol Moreno Spain 41 3.3k 2.6k 1.5k 1.0k 934 155 5.5k
Daniela Rottoli Italy 32 965 0.3× 357 0.1× 492 0.3× 1.5k 1.5× 179 0.2× 47 4.1k
Gunther Zahner Germany 34 300 0.1× 852 0.3× 760 0.5× 1.0k 1.0× 321 0.3× 63 3.9k
Changli Wei United States 27 580 0.2× 663 0.3× 651 0.4× 1.2k 1.2× 276 0.3× 61 4.2k
Kris Vaddi United States 26 1.1k 0.3× 214 0.1× 739 0.5× 1.5k 1.4× 909 1.0× 68 3.7k
Shinji Takai Japan 34 650 0.2× 174 0.1× 1.1k 0.8× 1.5k 1.5× 175 0.2× 147 3.8k
Takashi Murate Japan 32 504 0.2× 309 0.1× 426 0.3× 2.0k 1.9× 944 1.0× 137 3.5k
Anna Franca Milia Italy 25 433 0.1× 438 0.2× 277 0.2× 624 0.6× 188 0.2× 53 1.9k
Vera Eremina Canada 23 233 0.1× 310 0.1× 631 0.4× 2.3k 2.3× 223 0.2× 25 4.9k
Paola Cassis Italy 23 847 0.3× 113 0.0× 464 0.3× 838 0.8× 191 0.2× 40 3.1k
Fujio Shimizu Japan 35 283 0.1× 311 0.1× 569 0.4× 1.4k 1.4× 140 0.1× 118 3.7k

Countries citing papers authored by Carol Moreno

Since Specialization
Citations

This map shows the geographic impact of Carol Moreno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Moreno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Moreno more than expected).

Fields of papers citing papers by Carol Moreno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Moreno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Moreno. The network helps show where Carol Moreno may publish in the future.

Co-authorship network of co-authors of Carol Moreno

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Moreno. A scholar is included among the top collaborators of Carol Moreno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Moreno. Carol Moreno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Woyach, Jennifer A., Paolo Ghia, John C. Byrd, et al.. (2023). B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. Clinical Cancer Research. 29(16). 3065–3073. 7 indexed citations
2.
Ghia, Paolo, John N. Allan, Tanya Siddiqi, et al.. (2023). FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY. Hematological Oncology. 41(S2). 238–239. 1 indexed citations
3.
Moreno, Carol, Constantine S. Tam, Andrew Grigg, et al.. (2023). Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Advances. 7(18). 5294–5303. 10 indexed citations
4.
Kater, Arnon P., Carol Moreno, Talha Munir, et al.. (2023). P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL. HemaSphere. 7(S3). e56748d2–e56748d2. 1 indexed citations
5.
Ghia, Paolo, Talha Munir, Jan A. Burger, et al.. (2023). P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS. HemaSphere. 7(S3). e78258de–e78258de. 1 indexed citations
6.
Moreno, Carol, et al.. (2022). Post-urethroplasty fistula closure with PATIO technique: An alternative for the repair of urethro-cutaneous fistulas. European Urology Open Science. 44. S252–S253. 1 indexed citations
7.
Barr, Paul M., Carolyn Owen, Tadeusz Robak, et al.. (2022). Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia . Blood Advances. 6(11). 3440–3450. 146 indexed citations breakdown →
8.
Tam, Constantine S., John N. Allan, Tanya Siddiqi, et al.. (2022). Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 139(22). 3278–3289. 124 indexed citations breakdown →
9.
Moreno, Carol, et al.. (2021). Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. Journal of Experimental & Clinical Cancer Research. 40(1). 23 indexed citations
10.
Davids, Matthew S., Bryone J. Kuss, Peter Hillmen, et al.. (2020). Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research. 26(9). 2096–2103. 33 indexed citations
11.
Cuéllar‐García, Carolina, Salut Brunet, Javier Briones, et al.. (2018). Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy. Clinical Lymphoma Myeloma & Leukemia. 18(11). 737–742. 2 indexed citations
12.
O’Brien, Susan, Peter Hillmen, Steven Coutré, et al.. (2018). Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(10). 648–657.e15. 63 indexed citations
13.
Boqué, Concepción, et al.. (2017). Healthcare Professionals’ Preferences for the Treatment Selection of Chronic Lymphocytic Leukemia (CLL): The Prelic Study. Value in Health. 20(9). A455–A455. 1 indexed citations
14.
Kipps, Thomas J., Tadeusz Robak, Alessandra Tedeschi, et al.. (2016). Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM). Journal of the American Geriatrics Society. 64. 1 indexed citations
15.
Aktan, Meryem, Anna Schuh, Peter Johansson, et al.. (2015). Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukemia: primary results from the randomised phase IIIb MABLE study. Leukemia & lymphoma. 56. 149–149. 10 indexed citations
16.
Moreno, Carol, Timothy J. Stodola, Jozef Lazar, et al.. (2011). Creation and Characterization of a Renin Knockout Rat. Hypertension. 57(3). 614–619. 56 indexed citations
17.
Lucidi, Valério, et al.. (2008). Liver transplantation for acute liver failure in adults. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 1 indexed citations
18.
Bilušić, Marijo, Carol Moreno, Michael Tschannen, et al.. (2008). Genetically Hypertensive Brown Norway Congenic Rat Strains Suggest Intermediate Traits Underlying Genetic Hypertension. Croatian Medical Journal. 49(5). 586–599. 7 indexed citations
19.
Sharma, Mukut, Yvonne H. Datta, Carol Moreno, et al.. (2005). Rf-2 Gene Modulates Proteinuria and Albuminuria Independently of Changes in Glomerular Permeability in the Fawn-Hooded Hypertensive Rat. Journal of the American Society of Nephrology. 16(4). 852–856. 50 indexed citations
20.
Lazar, Jozef, Carol Moreno, Howard J. Jacob, & Anne E. Kwitek. (2005). Impact of genomics on research in the rat. Genome Research. 15(12). 1717–1728. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniela Rottoli Breakdown of academic impact, for papers by Gunther Zahner Breakdown of academic impact, for papers by Changli Wei Breakdown of academic impact, for papers by Kris Vaddi Breakdown of academic impact, for papers by Shinji Takai Breakdown of academic impact, for papers by Takashi Murate Breakdown of academic impact, for papers by Anna Franca Milia Breakdown of academic impact, for papers by Vera Eremina Breakdown of academic impact, for papers by Paola Cassis Breakdown of academic impact, for papers by Fujio Shimizu
Rankless by CCL
2026